MTOR and head and neck squamous cell carcinoma: The latter approach revealed that in HNSCC, metformin decreases mTOR and AKT activity, activates AMPK, and reduces the expression of cancer stemness gene-expression programs, thereby reducing the proliferative capacity of the precancer cells and enhancing their commitment to terminal differentiation (29).